Please ensure Javascript is enabled for purposes of website accessibility
Corbus Pharmaceuticals Stock Quote

Corbus Pharmaceuticals (NASDAQ: CRBP)

Price as of June 8, 2023, 10:09 a.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Corbus Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CRBP +12.30% -94.50% -44.02% -89%
S&P +3.94% +54.63% +9.11% +118%

Corbus Pharmaceuticals Company Info

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

News & Analysis

The Fool has written over 100 articles on Corbus Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.